- Home
- SDRL vs MNKD Comparison
SDRL vs MNKD Comparison
Compare SDRL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDRL
- MNKD
- Stock Information
- Founded
- SDRL 2005
- MNKD 1991
- Country
- SDRL Bermuda
- MNKD United States
- Employees
- SDRL N/A
- MNKD N/A
- Industry
- SDRL Oil & Gas Production
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- SDRL Energy
- MNKD Health Care
- Exchange
- SDRL Nasdaq
- MNKD Nasdaq
- Market Cap
- SDRL 1.3B
- MNKD 1.4B
- IPO Year
- SDRL N/A
- MNKD 2004
- Fundamental
- Price
- SDRL $23.21
- MNKD $4.15
- Analyst Decision
- SDRL Strong Buy
- MNKD Strong Buy
- Analyst Count
- SDRL 5
- MNKD 5
- Target Price
- SDRL $56.25
- MNKD $9.40
- AVG Volume (30 Days)
- SDRL 766.5K
- MNKD 1.9M
- Earning Date
- SDRL 05-12-2025
- MNKD 05-08-2025
- Dividend Yield
- SDRL N/A
- MNKD N/A
- EPS Growth
- SDRL 37.29
- MNKD 228.27
- EPS
- SDRL 5.56
- MNKD 0.10
- Revenue
- SDRL $1,288,000,000.00
- MNKD $297,595,000.00
- Revenue This Year
- SDRL $4.03
- MNKD $14.36
- Revenue Next Year
- SDRL $8.99
- MNKD $13.36
- P/E Ratio
- SDRL $4.17
- MNKD $40.01
- Revenue Growth
- SDRL N/A
- MNKD 32.50
- 52 Week Low
- SDRL $17.74
- MNKD $4.05
- 52 Week High
- SDRL $56.46
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- SDRL 49.64
- MNKD 37.04
- Support Level
- SDRL $22.30
- MNKD $4.07
- Resistance Level
- SDRL $24.41
- MNKD $4.25
- Average True Range (ATR)
- SDRL 0.90
- MNKD 0.16
- MACD
- SDRL -0.06
- MNKD -0.03
- Stochastic Oscillator
- SDRL 27.33
- MNKD 12.82
About SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.